The landscape for accessing GLP-1 medications, such as Ozempic and Wegovy, is shifting as insurance companies re-evaluate their coverage policies. While initial trends showed a rise in employer-sponsored plans covering these drugs, recent data indicates a move toward restriction. As of 2026, approximately two-thirds of private employer plans provided coverage for these treatments, but insurers are now citing the high monthly costs of the drugs as a primary driver for limiting access.

There is a clear divide in how this affects different patient populations. For individuals with high disposable income, the drugs remain accessible as an out-of-pocket expense. However, for lower-income workers who rely on employer-sponsored insurance to manage weight-related health conditions, the loss of coverage effectively bars them from treatment. The financial burden of these drugs, which can reach hundreds of dollars per month, makes insurance coverage the deciding factor in whether a patient can maintain their prescription.

While the industry initially embraced these drugs as a way to manage chronic health issues, the sheer volume of demand and the long-term price tag have led many plans to tighten their criteria. This creates a scenario where access to medical weight management is increasingly determined by socioeconomic status rather than clinical need alone.